Minerva Neurosciences
NERV
90 hedge funds and large institutions have $192M invested in Minerva Neurosciences in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 35 reducing their positions, and 13 closing their positions.
209% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $4.05M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.18% less ownership
Funds ownership: 10.37% → 10.19% (-0.18%)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 92 → 90 (-2)
16% less capital invested
Capital invested by funds: $230M → $192M (-$37.7M)
29% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$5.19M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.39M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.35M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.18M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.18M |
| 2 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$2.37M |
| 3 |
JP Morgan Chase
New York
|
-$2.21M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.08M |
| 5 |
AC
Armistice Capital
New York
|
-$1.96M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Voloridge Investment Management
Jupiter,
Florida
| – | -$82K | -1,433 | Closed |
|
102
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$27K | -471 | Closed |
|
|
APWM
103
Atlas Private Wealth Management
Albany,
New York
| – | -$2K | -31 | Closed |
|
NERV Hedge Fund Activity: Q1 2020 in Review
90 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2020, worth a combined $192M — down 16% from $230M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NERV and 12 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 25 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $5.19M. The largest seller was Sphera Funds Management, cutting an estimated $5.18M.
- 90 institutional investors held Minerva Neurosciences (NERV) as of Q1 2020, down from 92 in Q4 2019.
- Funds reported $192M of Minerva Neurosciences stock for Q1 2020, down 16% quarter-over-quarter.
- 12 funds opened new Minerva Neurosciences positions in Q1 2020 and 13 closed out, a net change of -1 holder.
- The largest Minerva Neurosciences buyer in Q1 2020 was Baker Bros. Advisors, an estimated $5.19M added.
- The largest Minerva Neurosciences seller in Q1 2020 was Sphera Funds Management, an estimated $5.18M sold.
Based on aggregated 13F filings for Q1 2020.